Risk and prevention of thromboembolic events in COVID-19 disease

█ Review

DOI: 10.26430/CHUNGARICA.2022.52.5.392

Authors:
Nagy-Kardos Cintia¹, Tihanyi László¹, Veress Gábor¹, Merkely Béla², Aradi Dániel^{1, 2
1}Állami Szívkórház, Balatonfüred
²Semmelweis Egyetem, Városmajori Szív- és Érgyógyászati Klinika, Budapest

Summary

Depending on the severity of the disease, a significant proportion of arterial and venous thromboembolic events may occur in COVID-19 patients, which are responsible for the high mortality of the infection. The prevalence of thromboembolic events exceeds the prevalence that can be seen in other viral infections (e.g. influenza). Emphasizing the significant procoagulant activity of the SARS-CoV-2 coronavirus and the immune response in the development of the coagulation disorder, the medical literature refers it as an independent COVID-coagulopathy, the prevention of which is a great challenge in daily practice. Fortunately, based on international data, the new variants of the constantly mutating virus, starting with the omicron variant, mean a milder disease and a lower risk of thromboembolism, but it is questionable how this risk will develop with future variants. The purpose of the review is to summarize the characteristics and pathophysiological background of the COVID-coagulopathy, as well as to present the results of clinical studies that have been performed to prevent these complications, highlighting the possible importance of anticoagulant and antiplatelet treatment.ls.

ISSUE: CARDIOLOGIA HUNGARICA | 2022 | VOLUME 52, ISSUE 5